ライフサイエンスコーパス: mother-to-child transmission

1 d life years, including due to a decrease in mother to child transmission.

2 r IPD in pregnancy and strategies to prevent mother-to-child transmission.

3 ad to interventions that reduce the risk for mother-to-child transmission.

4 with consequences for clinical outcomes and mother-to-child transmission.

5 to explaining the adverse effect of VA/BC on mother-to-child transmission.

6 that prenatal HIV screening reduced risk of mother-to-child transmission.

7 e mothers over the entire period of risk for mother-to-child transmission.

8 fective therapies and precautions to prevent mother-to-child transmission.

9 however yet challenges remain in eliminating mother-to-child transmission.

10 rranted for individuals who acquired HIV via mother-to-child transmission.

11 b-Saharan Africa, and by extension, reducing mother-to-child transmission.

12 m use of interventions to reduce the risk of mother-to-child transmission.

13 substantial benefit in reducing the rate of mother-to-child transmission.

14 inder of the time horizon and accounting for mother-to-child transmission.

15 have investigated the viral determinants of mother-to-child transmission.

16 xposed to nevirapine (NVP) for prevention of mother-to-child transmission.

17 HIV prevention, including the prevention of mother-to-child transmission.

18 dren exposed to nevirapine for prevention of mother-to-child transmission.

19 evolution was observed in the children after mother-to-child transmission.

20 (per 1,000 days) compared with 0.06-0.51 for mother-to-child transmission.

21 ne ART, the impact of drugs given to prevent mother-to-child transmission, adherence issues and, avai

22 o eliminate HIV transmission attributable to mother-to-child transmission and blood transfusions.

23 ildren, HIV-exposed neonates at high risk of mother-to-child transmission and children requiring conf

24 n the current era of effective prevention of mother-to-child transmission and early infant diagnosis

25 ve valuable in protocols aimed at preventing mother-to-child transmission and establishment of infect

26 ere considered as having HBV of high risk of mother-to-child transmission and initiated on oral tenof

27 level (viral load [VL]) is a risk factor for mother-to-child transmission and poor maternal health.

28 women to identify those at high risk for HBV mother-to-child transmission and to provide them with an

29 months were used to estimate proportions of mother-to-child transmission and transmission risks duri

30 dren exposed to nevirapine for prevention of mother-to-child transmission and with initial viral supp

31 velopment of resistance (the exception being mother-to-child transmission) and various combination dr

32 usly exposed to nevirapine for prevention of mother-to-child transmission, and achieved virological s

33 ations in scalable options for prevention of mother-to-child transmission, and ambitious population-w

34 understanding of HIV, ART, and prevention of mother-to-child transmission, and difficulty managing pr

35 otential for blood-transfusion transmission, mother-to-child transmission, and the development of new

36 cal circumcision, antiretrovirals to prevent mother-to-child transmission, antiretroviral therapy in

37 antiretroviral (ARV) therapy for preventing mother-to-child transmission are indisputable, studies i

38 -exposure prophylaxis, and the prevention of mother-to-child transmission, as well as listings of mut

39 The overall rate of mother-to-child transmission at 6-8 weeks was 15.3% in 4

40 viral quasispecies found in mothers, the HIV mother-to-child transmission bottleneck favors the trans

41 rologic suppression in a large prevention of mother-to-child transmission cohort who delivered in som

42 of opportunistic infections or prevention of mother-to-child transmission did not alter our findings.

43 itor regimens in children with prevention of mother-to-child transmission exposure may reduce risk of

44 In developed countries, the rate of mother-to-child transmission from untreated HIV-infected

45 Mother-to-child transmission; harms of screening and tre

46 iency virus (HIV) infection acquired through mother-to-child transmission has important clinical and

47 Critically, fatal cases and mother-to-child transmission have also been described.

48 nd postnatal interventions to prevent HTLV-1 mother-to-child transmission in Brazil and to develop an

49 e living with HIV infection acquired through mother-to-child transmission in New York City.

50 luded to assess the timing and likelihood of mother-to-child transmission in SARS-CoV-2 positive babi

51 toward achieving the goal of elimination of mother-to-child transmission in the region.

52 ication was used to categorise the timing of mother-to-child transmission (in utero, intrapartum, ear

53 TC/LPV/r suggests a lasting impact of failed mother-to-child transmission interventions on DRMs.

54 Mother-to-child transmission is a major route for infect

55 While mother-to-child transmission is believed to play in impo

56 me and how breast-milk virus correlates with mother-to-child transmission is important for establishi

57 after receipt of single-dose NVP to prevent mother-to-child transmission is not well defined.

58 During in utero mother-to-child transmission (IU MTCT), transmitted vira

59 th Africa were enrolled in the prevention of mother-to-child transmission Kesho Bora trial and counse

60 h some new cohort studies reporting rates of mother-to-child transmission less than 1% when combinati

61 tion antiretroviral therapy reduces rates of mother-to-child transmission (<1% to 2.4% vs. 9% to 2

62 IMPORTANCE As mother to child transmission (MTCT) of HIV plays a major

63 ion women will provide insight into risks of mother to child transmission (MTCT).

64 uring late pregnancy is permitted to prevent Mother-to-child transmission (MTCT) but discontinued at

65 ophylaxis to prevent hepatitis B virus (HBV) mother-to-child transmission (MTCT) in highly viremic mo

66 in late pregnancy for preventing hepatitis B mother-to-child transmission (MTCT) in real-world settin

67 With individual data from seven randomised mother-to-child transmission (MTCT) intervention trials,

68 Reducing hepatitis B virus (HBV) mother-to-child transmission (MTCT) is a fundamental ste

69 Prevention of mother-to-child transmission (MTCT) is an indispensable

70 corporates maternal antiviral prophylaxis on mother-to-child transmission (MTCT) is limited using rea

71 ing generation, a proxy for the frequency of mother-to-child transmission (MTCT) of HBV in a region,

72 Mother-to-child transmission (MTCT) of HBV remains an im

73 Ab) are associated with an increased risk of mother-to-child transmission (MTCT) of HCV, HCV nAb tite

74 Despite full immunoprophylaxis, mother-to-child transmission (MTCT) of Hepatitis B Virus

75 Perinatal or mother-to-child transmission (MTCT) of hepatitis B virus

76 Mother-to-child transmission (MTCT) of hepatitis B virus

77 Poor nutrition may be associated with mother-to-child transmission (MTCT) of HIV and other adv

78 V and syphilis testing might help to prevent mother-to-child transmission (MTCT) of HIV and syphilis

79 breast milk was associated with the risk of mother-to-child transmission (MTCT) of HIV by breastfeed

80 The rate of mother-to-child transmission (MTCT) of HIV from breastfe

81 Prevention of mother-to-child transmission (MTCT) of HIV remains a maj

82 ion of sCD14 concentrations with the risk of mother-to-child transmission (MTCT) of HIV, we nested a

83 Mother-to-child transmission (MTCT) of HIV-1 has been as

84 The mechanism of mother-to-child transmission (MTCT) of HIV-1 is not well

85 Mother-to-child transmission (MTCT) of HIV-1 is the majo

86 RNA in breast milk and may therefore reduce mother-to-child transmission (MTCT) of HIV-1 via breast-

87 define humoral immune correlates of risk of mother-to-child transmission (MTCT) of HIV-1, including

88 ngle-dose NVP (SD-NVP) for the prevention of mother-to-child transmission (MTCT) of HIV-1.

89 new therapeutic strategies in prevention of mother-to-child transmission (MTCT) of HIV-1.

90 are well-established factors associated with mother-to-child transmission (MTCT) of HIV; the role of

91 cts on infant gut epithelia, and the risk of mother-to-child transmission (MTCT) of human immunodefic

92 protect against adverse pregnancy outcomes, mother-to-child transmission (MTCT) of human immunodefic

93 Risk factors for mother-to-child transmission (MTCT) of human immunodefic

94 ose nevirapine (sdNVP)-based regimens reduce mother-to-child transmission (MTCT) of human immunodefic

95 nal serum retinol level is a risk factor for mother-to-child transmission (MTCT) of human immunodefic

96 Nvp) prophylaxis is effective for preventing mother-to-child transmission (MTCT) of human immunodefic

97 Mother-to-child transmission (MTCT) of human immunodefic

98 significant progress in reducing peripartum mother-to-child transmission (MTCT) of human immunodefic

99 Mother-to-child transmission (MTCT) of human immunodefic

100 s a long-standing component of prevention of mother-to-child transmission (MTCT) of human immunodefic

101 Mother-to-child transmission (MTCT) of human T-lymphotro

102 ciency virus type 1 (HIV-1) acquired through mother-to-child transmission (MTCT) or failed chemoproph

103 or at least 4 weeks prior to testing, and a mother-to-child transmission (MTCT) rate at 12 months of

104 virus type 1 (HIV-1) treatment outcomes, and mother-to-child transmission (MTCT) risk.

105 ission through the adult oral route is rare, mother-to-child transmission (MTCT) through the neonatal

106 tinues to cause the majority of new cases of mother-to-child transmission (MTCT), and yet there are l

107 ART can dramatically reduce HIV mother-to-child transmission (MTCT), but inconsistent dr

108 HBV) is not achievable without prevention of mother-to-child transmission (MTCT).

109 is known about the viral determinants of HIV mother-to-child transmission (MTCT).

110 tial intervention to prevent postnatal HIV-1 mother-to-child transmission (MTCT).

111 Mother-to-child-transmission (MTCT) of human immunodefic

112 cific IgG binding that predicted low risk of mother-to-child-transmission (MTCT) was dependent on the

113 oad > 50 copies/mL at third trimester and no mother-to-child transmission occurred.

114 whether these boosted responses may prevent mother to child transmission of CMV.

115 The frequency of perinatal mother to child transmission of HIV was increased in wom

116 MQ was associated with an increased risk of mother to child transmission of HIV, which warrants a be

117 It is yet to be investigated but mother to child transmission of TCS or similar toxicants

118 rologic suppression, with an overall rate of mother-to-child transmission of 1.1%.

119 Mother-to-child transmission of CD8+ T cell escape varia

120 erogeneity of gag and nef gene sequences and mother-to-child transmission of CD8+ T cell escape varia

121 cell recognition of B57-restricted epitopes, mother-to-child transmission of escape mutations within

122 of hepatitis B vaccine (HBV), which prevents mother-to-child transmission of HBV and subsequent liver

123 Mother-to-child transmission of HCV occurs in 3-5% of pr

124 he diagnosis and treatment of HCV infection, mother-to-child transmission of HCV, and possible virus-

125 Mother-to-child transmission of hepatitis B can be preve

126 tional age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there

127 Although the rate of mother-to-child transmission of hepatitis C virus (HCV)

128 information is available about the timing of mother-to-child transmission of hepatitis C virus (HCV),

129 ntly one of the highest burden countries for mother-to-child transmission of HIV (MTCT).

130 pite expansion of services for prevention of mother-to-child transmission of HIV (PMTCT), about 700 i

131 to access and sustain care for prevention of mother-to-child transmission of HIV (PMTCT), yet their c

132 toring (which is critical for elimination of mother-to-child transmission of HIV [eMTCT] and the heal

133 s of both antiretroviral prophylaxis against mother-to-child transmission of HIV and antiretroviral t

134 provide a new opportunity to further reduce mother-to-child transmission of HIV and propose that new

135 alaria and for the effect of co-infection on mother-to-child transmission of HIV are areas of major i

136 The mother-to-child transmission of HIV at birth was 8.1% (3

137 Interruption of ART would increase mother-to-child transmission of HIV by approximately 1.6

138 Rates of mother-to-child transmission of HIV in Ukraine have decl

139 the benefits (specifically, reduced risk of mother-to-child transmission of HIV infection) and harms

140 rently recommended ART regimens for reducing mother-to-child transmission of HIV infection, and the h

141 low-breastfeeding setting with a low risk of mother-to-child transmission of HIV is unclear.

142 Mother-to-child transmission of HIV remains a significan

143 beta-carotene (VA/BC) increases the risk of mother-to-child transmission of HIV through breastfeedin

144 rogrammes to reduce child undernutrition and mother-to-child transmission of HIV, and some improvemen

145 le-dose nevirapine (sdNVP) for prevention of mother-to-child transmission of HIV-1 can select nevirap

146 ential clinical importance, target cells for mother-to-child transmission of HIV-1 have not yet been

147 single dose of nevirapine (sdNVP) to prevent mother-to-child transmission of HIV-1 increases the risk

148 l secretions and breast milk and the risk of mother-to-child transmission of HIV-1 were compared amon

149 ipated in a study of sdNVP for prevention of mother-to-child transmission of HIV-1.

150 uppression before giving birth and increased mother-to-child transmission of HIV.

151 s an important opportunity for prevention of mother-to-child transmission of HIV.

152 ses (e.g., malaria) may increase the risk of mother-to-child transmission of HIV.

153 the use of intrapartum nevirapine to prevent mother-to-child transmission of HIV.

154 , low-breastfeeding areas with a low risk of mother-to-child transmission of HIV.

155 Mother-to-child transmission of human immunodeficiency v

156 oviral (ARV) prophylaxis effectively reduces mother-to-child transmission of human immunodeficiency v

157 retroviral therapy (HAART) for prevention of mother-to-child transmission of human immunodeficiency v

158 Mother-to-child transmission of human immunodeficiency v

159 cornerstone of the regimen for prevention of mother-to-child transmission of human immunodeficiency v

160 nistration of single-dose nevirapine reduces mother-to-child transmission of human immunodeficiency v

161 ve antiretroviral therapy (HAART) to prevent mother-to-child transmission of human immunodeficiency v

162 Intrapartum single-dose nevirapine decreases mother-to-child transmission of human immunodeficiency v

163 To reduce mother-to-child transmission of human immunodeficiency v

164 bed to pregnant women at delivery, to reduce mother-to-child transmission of human immunodeficiency v

165 ive strategies are urgently needed to reduce mother-to-child transmission of human immunodeficiency v

166 (SD) nevirapine (NVP) significantly reduces mother-to-child transmission of human immunodeficiency v

167 use of antiretroviral (ARV) drugs to prevent mother-to-child transmission of human immunodeficiency v

168 ution of neutralizing antibodies in limiting mother-to-child transmission of human immunodeficiency v

169 tum dose of nevirapine for the prevention of mother-to-child transmission of human immunodeficiency v

170 order and delivery route as risk factors for mother-to-child transmission of human immunodeficiency v

171 The rates of mother-to-child transmission of human immunodeficiency v

172 Mother-to-child transmission of human immunodeficiency v

173 Mother-to-child transmission of human immunodeficiency v

174 d CD4+ T cells, thus potentially influencing mother-to-child transmission of human immunodeficiency v

175 viral therapy (ART) is crucial to preventing mother-to-child transmission of human immunodeficiency v

176 pregnancy are highly effective in preventing mother-to-child transmission of human immunodeficiency v

177 ed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency v

178 provirus load in breast milk and the risk of mother-to-child transmission of human T lymphotropic vir

179 d a global initiative for the elimination of mother-to-child transmission of syphilis (congenital syp

180 timing of antenatal interventions to prevent mother-to-child transmission of syphilis and its associa

181 WHO's global health initiative to eliminate mother-to-child transmission of syphilis be made feasibl

182 oportion of women who access antenatal care, mother-to-child transmission of syphilis continues to be

183 ntribute to improving prevention efforts for mother-to-child transmission of syphilis, such as early

184 is the only recommended treatment to prevent mother-to-child transmission of syphilis.

185 l important for achieving the elimination of mother-to-child transmission of syphilis.

186 suggests progress towards the elimination of mother-to-child transmission of syphilis.

187 It will highlight mother-to-child transmission of viral hepatitis, both ma

188 te to the transmission bottleneck.IMPORTANCE Mother-to-child-transmission of HIV-1 offers a unique se

189 gle-dose nevirapine (sdNVP) given to prevent mother-to-child-transmission of HIV-1 selects NVP-resist

190 immune response biomarkers in the context of Mother-To-Child-Transmission of HIV-1 viruses.

191 e-limited settings where, in efforts to stem mother-to-child-transmission of HIV-1, transient nonnucl

192 cohort studies of pregnant women on risk for mother-to-child transmission or harms associated with pr

193 ffects of prenatal HIV screening on risk for mother-to-child transmission or maternal or infant clini

194 line HIVDR (P = .04), maternal prevention of mother-to-child transmission (P = .02), and estimated da

195 itted variants, we analyzed 5 viruses from 2 mother-to-child transmission pairs, in which the infant

196 alleles in viral variants obtained from five mother-to-child transmission pairs.

197 se vaccination to existing HIV prevention of mother-to-child transmission platforms is feasible in co

198 nd to have higher adherence to Prevention of Mother to Child Transmission (PMTCT) guidelines, compare

199 utine neonatal vaccination and prevention of mother to child transmission (PMTCT; at 100% coverage).

200 ss years of life saved through prevention of mother-to-child transmission (PMTCT) and ART.

201 natal HIV prevalence and > 80% prevention of mother-to-child transmission (PMTCT) coverage.

202 Prevention of mother-to-child transmission (PMTCT) has proven an effec

203 (HIV-1) RNA in the context of prevention of mother-to-child transmission (PMTCT) interventions is un

204 vement interventions (CQI) for prevention of mother-to-child transmission (PMTCT) of HIV (CQI-PMTCT s

205 ractive text-messages improved prevention of mother-to-child transmission (PMTCT) of HIV care outcome

206 s, treatment with ART, and the prevention of mother-to-child transmission (pMTCT) of HIV.

207 Prevention of mother-to-child transmission (PMTCT) of human immunodefi

208 Programs for the prevention of mother-to-child transmission (PMTCT) of human immunodefi

209 diatric HIV epidemic by making prevention of mother-to-child transmission (PMTCT) services accessible

210 Such objectives require regimens to prevent mother-to-child transmission (pMTCT) which, while being

211 mong children infected despite prevention of mother-to-child transmission (PMTCT), a substantial prop

212 reexposure prophylaxis (PrEP), prevention of mother-to-child transmission (PMTCT), and postexposure p

213 ssion rates (2.5%), due to HIV prevention of mother-to-child transmission program improvements in Sou

214 ng the already established HIV prevention of mother-to-child transmission programme at these two mate

215 gramme on Immunisation and HIV prevention of mother-to-child transmission programme could accelerate

216 whose mothers are accessing a prevention of mother-to-child transmission programme in an area unaffe

217 HBV-exposed infants to the HIV prevention of mother-to-child transmission programme infrastructure in

218 for CHTC in Malawi's option B+ prevention of mother-to-child transmission programme: invitation only

219 untries outside the context of prevention of mother-to-child transmission programmes provides an impo

220 Prevention of mother-to-child transmission programs have been one of t

221 The setting of mother-to-child transmission provides an opportunity to

222 well established prevention programmes keep mother-to-child transmission rates at less than 2%.

223 In resource-rich countries, mother-to-child transmission rates of HIV as low as 1% h

224 ction in pregnant women can greatly decrease mother-to-child transmission rates.

225 likely attributable to long-term survival of mother-to-child transmission rather than increases in ri

226 global efforts to scale up the prevention of mother-to-child transmission services and pediatric anti

227 ale-up in antiretroviral-based prevention of mother-to-child transmission services, more than 250 000

228 d type and timing of tests, 14 had confirmed mother-to-child transmission: seven in utero (448 assess

229 breastfeeding, indicating a mucosal route of mother-to-child transmission that can be targeted in pre

230 rotease-driven viral replication capacity on mother-to-child transmission, the replication capacities

231 h increased levels of milk HIV-1 and risk of mother-to-child transmission through breastfeeding.

232 sent study, we examined 2 possible routes of mother-to-child transmission, through breast milk and sa

233 the use of antiretroviral therapy to prevent mother-to-child transmission to the possibility of HIV c

234 After the period of risk of mother-to-child transmission was over, women were random

235 No cases of HBV mother-to-child transmission were observed.

236 dren exposed to nevirapine for prevention of mother-to-child transmission who were aged 3 years or ol

237 is highly effective at reducing the risk of mother-to-child transmission, with some new cohort studi

238 mentation of interventions to prevent HTLV-1 mother-to-child transmission worldwide.